Gilead shares are trading lower after the company's Phase 3 TROPiCS-04 study missed its primary endpoint of overall survival.

Gilead Sciences, Inc. +2.32%

Gilead Sciences, Inc.

GILD

73.30

+2.32%

Gilead shares are trading lower after the company's Phase 3 TROPiCS-04 study missed its primary endpoint of overall survival.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via